依折麦布(Ezetimibe) - 药物靶点：NPC1L1_在研适应症：高脂血症，高胆固醇血症，心血管疾病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Absorcol、Ezedoc、Ezetimibe (JAN/USP/INN)

+ [12]

靶点

NPC1L1

作用方式

抑制剂

作用机制

NPC1L1抑制剂(尼曼-匹克C1型类似蛋白-1抑制剂)、胆固醇吸收抑制剂

治疗领域

心血管疾病遗传病与畸形消化系统疾病+ [2]

在研适应症

高脂血症高胆固醇血症心血管疾病+ [4]

非在研适应症

动脉粥样硬化冠心病冠状动脉疾病+ [4]

原研机构

Merck Sharp & Dohme Corp.

在研机构

Organon & Co.Merck Sharp & Dohme LLCOrganon Pharma Pty Ltd.

+ [2]

非在研机构

Schering-Plough Corp.

最高研发阶段批准上市

首次获批日期

美国 (2002-10-25),

纯合子家族性高胆固醇血症原发性高胆固醇血症谷甾醇血症

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C24H21F2NO3

InChIKeyOLNTVTPDXPETLC-XPWALMASSA-N

CAS号163222-33-1

关联

367

项与依折麦布相关的临床试验

NCT06722521

/ Not yet recruiting临床4期IIT

Comparison of Intensive Lipid-Lowering Therapy With a Statin-Ezetimibe Combination (Without Aspirin) vs. Statin Monotherapy (With Aspirin) In Asymptomatic Patient With Coronary Artery Calcification

A Multicenter, randomized trial comparing the efficacy and safety of intensive lipid-lowering therapy using a statin-ezetimibe combination without aspirin versus statin monotherapy with aspirin in asymptomatic patients with coronary artery calcification

开始日期2025-05-01

申办/合作机构

Asan Medical Center

NCT06858332

/ Not yet recruitingN/A

Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia

This study has the purpose to answer how the Lipoprotein(a) (Lp(a)) level is distributed among Atherosclerotic cardiovascular disease (ASCVD) patients in Russia, and what is the connection between elevated levels of this parameter and the cardiovascular disease (CVD) risk.

开始日期2025-03-31

申办/合作机构

Novartis Pharmaceuticals Canada, Inc.

NCT06686615

/ Not yet recruitingN/A

Effectiveness and Safety of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia: an Observational Study

Data on the real-world use and effectiveness and safety of bempedoic acid combined with both a statin and ezetimibe in clinical practice is limited. There is an increased focus on using combination therapy to lower LDL-C.

开始日期2025-03-03

申办/合作机构

Daiichi Sankyo Europe GmbH

100 项与依折麦布相关的临床结果

登录后查看更多信息

100 项与依折麦布相关的转化医学

登录后查看更多信息

100 项与依折麦布相关的专利（医药）

登录后查看更多信息

6,330

项与依折麦布相关的文献（医药）

2025-05-01·JOURNAL OF PHARMACEUTICAL SCIENCES

Ezetimibe alters micelle structure and reduces Niemann-Pick C1-like 1-mediated absorption of vitamins E and K1 in CaCo-2 cells

Article

作者: Aizawa, Hideki

Ezetimibe (EZE) is known to inhibit cholesterol absorption by targeting Niemann-Pick C1-like 1 (NPC1L1). However, its effects on the absorption of fat-soluble vitamins, such as Vitamin E and Vitamin K₁, remain unclear. This study investigates how EZE impacts micellar properties and vitamin absorption. We analyzed the shape, size, diffusion rate, and zeta-potential of micelles during Vitamin E and K₁ absorption. Our findings demonstrate that EZE causes micelles to transition from an elliptical to a cylindrical shape, reducing vitamin absorption efficiency. EZE also impairs absorption by altering micelle composition, hindering NPC1L1 binding, and directly blocking vitamin uptake. EZE negatively affects Vitamin E and K₁ absorption, raising concerns about potential deficiencies with long-term use. These findings highlight the need for strategies to minimize the adverse effects of EZE in clinical practice.

2025-04-01·JOURNAL OF INVESTIGATIVE DERMATOLOGY

PCSK9 Inhibitors and the Risk of Vitiligo: A Mendelian Randomization Study

Article

作者: Lee, Sun Yeop ; Yoon, Sanghyuk ; Kang, Tae-Jong ; Park, Jin ; Kim, Eun Gyo ; Kim, Jung Oh ; Kim, Jong-Seung ; Nam, Kyung-Hwa

Lipid-lowering agents have been suggested as a therapeutic option for vitiligo on the basis of the potential pathogenic role of lipid metabolism abnormalities. We aimed to explore the impact of genetically proxied lipid-lowering agents on the risk of vitiligo and potentially associated mediators. GWAS summary statistics for European ancestry were extracted from the largest available meta-analysis for vitiligo: the Global Lipids Genetics Consortium for 7 lipid profiles and 2 large biobanks, UK Biobank and deCODE, for 4719 proteins. After identifying lipid-lowering agents with genetically proxied protective effects against vitiligo using lipid-lowering and protein-inhibition Mendelian randomization (MR) analyses, multivariable and 2-step MR analyses were conducted to identify potential mediators between lipid-lowering agents and vitiligo. Lipid-lowering MR indicated a potential role of PCSK9 in reducing the vitiligo risk (OR [95% confidence interval] = 0.71 [0.52-0.95]), which was replicated in PCSK9-inhibition MR analyses across 2 separate biobanks (UK Biobank: OR [95% confidence interval] = 0.82 [0.71-0.96]; deCODE: OR [95% confidence interval] = 0.78 [0.67-0.91]). Multivariable MR suggested that well-known lipid profiles do not mediate the relationship between PCSK9 and vitiligo, whereas 2-step MR analyses identified 5 potential protein mediators (CCN5, CXCL12, FCRL1, legumain, and FGF2). Hence, PCSK9 inhibitor may attenuate the vitiligo risk; PCSK9 and the potential protein mediators can serve as promising novel therapeutic targets for its effective treatment.

2025-04-01·TOXICOLOGY AND APPLIED PHARMACOLOGY

Sodium taurocholate co-transporting polypeptide deficiency attenuates acetaminophen-induced hepatotoxicity via regulating expression of drug metabolism enzymes in mice

Article

作者: Zhu, Shu ; Xu, Wenxiong ; Zhang, Yuzhen ; Wu, Yuankai ; Yang, Fangji ; Wu, Lina ; Peng, Liang ; Chong, Yutian

Acetaminophen (APAP) overdose can induce liver injury and is generally accompanied by disruption of bile acid homeostasis. Physiologically, sodium taurocholate co-transporting polypeptide (NTCP) participates in the uptake of bile acids from portal blood into hepatocytes to maintain enterohepatic recirculation but its role in APAP-induced hepatotoxicity is unclear. Wild-type (WT) C57BL/6J and NTCP knockout (KO) mice were injected with 400mg/kg APAP and liver injury was evaluated by serum biochemical markers and histologic evaluation. RNA-seq analysis was performed to evaluate the liver gene expression profiles in APAP-treated mice. Compared with WT mice, the exposure to APAP overdose caused liver dysfunction, oxidative stress, inflammation and cell death, which were ameliorated by NTCP deficiency. APAP detoxification, metabolism, and elimination were significantly accelerated by the upregulation of UDP-glucuronosyltransferase (Ugt1a1, Ugt1a6 and Ugt1a9), sulfotransferase (Sult1a1 and Sult2a1) and bile acid efflux transporters (Abcc2/3/4) in NTCP KO mice compared with WT mice. Interestingly, APAP-induced hepatotoxicity was ameliorated using Irbesartan and Ezetimibe (NTCP inhibitors). In conclusion, NTCP deficiency attenuates APAP-induced hepatotoxicity by enhancing the metabolism and elimination of APAP. NTCP inhibitors protect against APAP-induced hepatotoxicity and thus are a potential therapeutic option.

390

项与依折麦布相关的新闻（医药）

2025-03-25

·drugs

Two-Drug Combo Lowers Cholesterol Better Than Statins Alone

TUESDAY, March 25, 2025 -- Statins are very cheap and highly effective cholesterol-lowering drugs -- but high-risk heart patients may have an even better option, a new evidence review says. Combining statins with another drug, ezetimibe , significantly reduces the risk of death in patients with clogged arteries, according to findings published March 23 in Mayo Clinic Proceedings . Using a high-dose statin with ezetimibe significantly reduces levels of “bad” LDL cholesterol, increasing a person’s chances of reaching healthy levels by 85%, researchers found. The combo also brought about a 19% reduction in risk of death from any cause; a 16% reduction in heart-related deaths; an 18% decrease in the risk of a major cardiovascular health problem; and a 17% decline in stroke risk. This combination therapy would prevent more than 330,000 deaths a year worldwide among patients who have already suffered a heart attack, including almost 50,000 deaths in the U.S. alone, researchers said. “This study confirms that combined cholesterol lowering therapy should be considered immediately and should be the gold standard for treatment of very high-risk patients after an acute cardiovascular event,” senior researcher Dr. Peter Toth , a professor of clinical family and community medicine at the University of Illinois, said in a news release. Up to now, studies have been inconsistent regarding whether to provide combo cholesterol-lowering therapy immediately for high-risk patients, even before they suffer a heart attack or stroke . Typically, doctors wait at least two months before adding any medication to a statin, to see how well statins alone will lower cholesterol, Toth said. “This approach does not require additional funding or reimbursement of new expensive drugs,” he said. “In fact, it may translate into lower rates of first and subsequent heart attacks and stroke, and their complications like heart failure, which are extremely costly for all healthcare systems.” For the new evidence review, researchers pooled data from 14 studies involving more than 108,000 heart patients at very high risk for a heart attack, stroke or other heart-related health problem. Results were even more pronounced in an additional analysis that enabled a direct comparison of different therapies, researchers said. “This showed a 49% reduction in all-cause mortality and a 39% reduction in major adverse cardiovascular events, when compared to high dose statin therapy alone,” said lead researcher Dr. Maciej Banach , a professor of cardiology at the John Paul II Catholic University of Lublin in Poland. Ezetimibe works by reducing the amount of cholesterol the intestines can absorb from food. Statins have a different mechanism – they work by interfering with the liver’s ability to make cholesterol. Both drugs are available as inexpensive generics. “Our findings underline the importance of the adages ‘the lower for better for longer’ but also the equally important ‘the earlier the better’ for treating patients at high risk of cardiovascular conditions and to avoid further medical complications and deaths,” Toth said. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

AHA会议

2025-03-25

·drugs

Two-Drug Combo of a Statin Plus Ezetimibe, Lowers Cholesterol Better Than Statins Alone

TUESDAY, March 25, 2025 -- Statins are very cheap and highly effective cholesterol-lowering drugs -- but high-risk heart patients may have an even better option, a new evidence review says. Combining statins with another drug, ezetimibe , significantly reduces the risk of death in patients with clogged arteries, according to findings published March 23 in Mayo Clinic Proceedings . Using a high-dose statin with ezetimibe significantly reduces levels of “bad” LDL cholesterol, increasing a person’s chances of reaching healthy levels by 85%, researchers found. The combo also brought about a 19% reduction in risk of death from any cause; a 16% reduction in heart-related deaths; an 18% decrease in the risk of a major cardiovascular health problem; and a 17% decline in stroke risk. This combination therapy would prevent more than 330,000 deaths a year worldwide among patients who have already suffered a heart attack, including almost 50,000 deaths in the U.S. alone, researchers said. “This study confirms that combined cholesterol lowering therapy should be considered immediately and should be the gold standard for treatment of very high-risk patients after an acute cardiovascular event,” senior researcher Dr. Peter Toth , a professor of clinical family and community medicine at the University of Illinois, said in a news release. Up to now, studies have been inconsistent regarding whether to provide combo cholesterol-lowering therapy immediately for high-risk patients, even before they suffer a heart attack or stroke . Typically, doctors wait at least two months before adding any medication to a statin, to see how well statins alone will lower cholesterol, Toth said. “This approach does not require additional funding or reimbursement of new expensive drugs,” he said. “In fact, it may translate into lower rates of first and subsequent heart attacks and stroke, and their complications like heart failure, which are extremely costly for all healthcare systems.” For the new evidence review, researchers pooled data from 14 studies involving more than 108,000 heart patients at very high risk for a heart attack, stroke or other heart-related health problem. Results were even more pronounced in an additional analysis that enabled a direct comparison of different therapies, researchers said. “This showed a 49% reduction in all-cause mortality and a 39% reduction in major adverse cardiovascular events, when compared to high dose statin therapy alone,” said lead researcher Dr. Maciej Banach , a professor of cardiology at the John Paul II Catholic University of Lublin in Poland. Ezetimibe works by reducing the amount of cholesterol the intestines can absorb from food. Statins have a different mechanism – they work by interfering with the liver’s ability to make cholesterol. Both drugs are available as inexpensive generics. “Our findings underline the importance of the adages ‘the lower for better for longer’ but also the equally important ‘the earlier the better’ for treating patients at high risk of cardiovascular conditions and to avoid further medical complications and deaths,” Toth said. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

AHA会议临床结果

2025-03-22

·丁香园

急性心梗诊疗：2025 最新指南推荐

急性冠脉综合征（Acute Coronary Syndrome，ACS）是心血管急症中最具挑战性的疾病之一，其病理生理机制复杂，治疗策略需兼顾快速干预与长期预后。2025 年 ACC/AHA/ACEP/NAEMSP/SCAI 联合发布的 ACS 管理指南在既往版本基础上进行了重要更新，整合了近年来的循证医学证据，尤其针对抗血小板治疗、再灌注策略、多支血管病变管理及心源性休克处理等方面提出了新建议。本文将从诊断评估、药物治疗、介入治疗、并发症管理及二级预防等维度系统解析指南核心内容，为临床医生提供实践参考。一 ACS 的定义与分类 ACS 涵盖一系列临床综合征，包括不稳定性心绞痛（Unstable Angina，UA）、非 ST 段抬高型心肌梗死（NSTEMI）和 ST 段抬高型心肌梗死（STEMI），其共同病理基础为冠状动脉粥样硬化斑块破裂或侵蚀引发的血栓形成。根据心电图（ECG）和高敏肌钙蛋白（hs-cTn）的动态变化，ACS 可进一步细分（图 1）： 1、STEMI：完全性冠状动脉闭塞导致透壁心肌缺血，ECG 表现为持续性 ST 段抬高（≥ 1 mm，除 V2～V3 导联外）或新发左束支传导阻滞（LBBB）。 2、NSTEMI：部分冠状动脉闭塞导致心内膜下缺血，ECG 可表现为 ST 段压低、T 波倒置或无特异性改变，但 hs-cTn 升高。 3、不稳定性心绞痛：心肌缺血未导致心肌坏死，hs-cTn 水平正常。图 1 急性冠脉综合征的类型和分类。NSTEMI 提示非 ST 段抬高型心肌梗死；STEMI 提示 ST 段抬高型心肌梗死关键点：快速识别 STEMI 至关重要，需在首次医疗接触（FMC）后 10 分钟内完成 ECG 并启动再灌注治疗。二初始评估与风险分层 1、院前与急诊评估（图 2）院前管理：疑似 ACS 患者应优先通过急救医疗系统（EMS）转运，EMS 人员需在 10 分钟内完成 12 导联 ECG 并解读。若确诊 STEMI，应直接转运至具备直接 PCI 能力的医院，目标 FMC 至首次器械时间 ≤ 90 分钟（直接就诊）或 ≤ 120 分钟（需转院）。院内评估：急诊科需在 10 分钟内完成 ECG，并立即检测 hs-cTn。对于初始 ECG 无诊断意义的患者，若症状持续或恶化，需动态监测 ECG 变化。图 2 疑似 ACS 患者的初始评估：ACS 提示急性冠脉综合征；CDP 提示临床决策途径；cTn 提示心肌肌钙蛋白；hs-cTn 提示高敏心肌肌钙蛋白；NSTEMI 提示非 ST 段抬高型心肌梗死；STEMI 提示 ST 段抬高型心肌梗死 2、风险分层工具 GRACE 风险评分：适用于评估住院期间及远期死亡风险，结合年龄、心率、收缩压、肌酐、Killip 分级、心肌标志物升高及 ST 段变化。 TIMI 风险评分：用于 NSTE-ACS 患者，预测 30 天内死亡、心梗或需紧急血运重建的风险。临床高危特征：包括心源性休克、持续胸痛、血流动力学不稳定、恶性心律失常或急性肺水肿，需立即侵入性评估。三药物治疗的核心策略 1、抗血小板治疗（表 1、图 3）阿司匹林：所有 ACS 患者应立即给予负荷剂量（162～325 mg），维持剂量 75～100 mg/天。 P2Y12 受体抑制剂：优先选择：替格瑞洛（负荷剂量 180 mg，维持90 mg bid）或普拉格雷（负荷剂量 60 mg，维持 10 mg qd），较氯吡格雷显著降低缺血事件风险。特殊情况：氯吡格雷适用于出血高风险、卒中/TIA 病史或无法耐受强效 P2Y12 抑制剂者。静脉抗血小板药物：坎格瑞洛可作为未预先使用 P2Y12 抑制剂患者的桥接治疗，尤其适用于需紧急手术者。表 1 ACS 患者口服抗血小板治疗的剂量考虑 NSTE-ACS 提示非 ST 段抬高急性冠脉综合征；PCI 提示经皮冠状动脉介入治疗；STEMI 提示 ST 段抬高型心肌梗死图 3 P2Y12 抑制剂在不需要口服抗凝剂患者中的初始选择。ACS 提示急性冠脉综合征；ASA 提示阿司匹林；CABG 提示冠状动脉旁路移植术；NSTE-ACS 提示非 ST 段抬高型 ACS；PCI提示经皮冠状动脉介入治疗；STEMI 提示 ST 段抬高型心肌梗死 2、抗凝治疗（表 2）初始抗凝：普通肝素（UFH）或依诺肝素为 NSTE-ACS 首选；STEMI 接受溶栓治疗者推荐依诺肝素或磺达肝癸。 PCI 术中抗凝：UFH 仍是金标准，比伐卢定可替代以降低出血风险（尤其经桡动脉路径）。表 2 ACS 肠外抗凝药的剂量 3、调脂治疗（图 4、表 3）高强度他汀：所有 ACS 患者启动阿托伐他汀（40～80 mg）或瑞舒伐他汀（20～40 mg），目标 LDL-C 降幅 ≥ 50%。非他汀类药物：若他汀治疗后 LDL-C ≥ 70 mg/dL，加用依折麦布或 PCSK9 抑制剂；LDL-C 55～69 mg/dL 且高危者可考虑强化治疗。图 4 ACS 患者的降脂治疗管理。*非他汀类 LDL 降低疗法：依折麦布、PCSK9 抑制剂（alirocumab、evolocumab 和 inclisiran）和/或 bempedoic acid。ACS 提示急性冠脉综合征；LDL 提示低密度脂蛋白；LDL-C 提示低密度脂蛋白胆固醇；PCSK9 提示前蛋白转化酶枯草杆菌蛋白酶/kexin 9 型表 3 他汀类药物分类高强度：预期预期 LDL-C 降低 ≥ 50%；中等强度：预期 LDL-C 降低 ≥ 30%～49%；低强度治疗：预期 LDL-C 降低 < 30% 4、其他辅助治疗 β 受体阻滞剂：无禁忌证者早期（< 24 小时）口服使用，降低再梗死及恶性心律失常风险。 ACEI/ARB：适用于左室射血分数（LVEF）≤ 40%、高血压、糖尿病或前壁 STEMI 患者。盐皮质激素受体拮抗剂：LVEF ≤ 40% 合并心衰或糖尿病者推荐使用。四再灌注策略：STEMI 与 NSTE-ACS 的差异化管理 1、STEMI 的再灌注治疗直接 PCI（PPCI）：为首选策略，目标 FMC 至球囊扩张时间 ≤ 90 分钟。若预计延迟 > 120 分钟，优先溶栓后转运 PCI。溶栓治疗：适用于无 PCI 条件且症状 < 12 小时者，推荐替奈普酶（TNK-tPA）或阿替普酶（rt-PA）。溶栓后需立即转运至 PCI 中心，2～24 小时内完成冠脉造影。完全血运重建：血流动力学稳定者，非罪犯血管严重狭窄（≥ 70%）建议同期或分期 PCI，降低远期 MACE 风险。 2、NSTE-ACS 的侵入性策略（图 5）高危/中危患者：推荐早期（高危 < 24 小时，中危 < 72 小时）侵入性策略，明确病变并实施血运重建。低危患者：可选择保守治疗，但需非侵入性评估（如负荷试验、冠脉 CTA）后决定后续干预。图 5 NSTE-ACS 中侵入性策略的选择和时机。GRACE 表示急性冠状动脉事件全球登记处；HF 表示心力衰竭；NSTE-ACS 表示非 ST 段抬高急性冠脉综合征；Tn 表示肌钙蛋白；TIMI 表示心肌梗死溶栓；VF 表示心室颤动；VT 表示室性心动过速五导管室操作的关键考量 1、血管入路选择经桡动脉路径：显著减少出血及血管并发症，降低死亡率，推荐为首选。经股动脉路径：适用于需要机械循环支持（如IABP、VA-ECMO）或桡动脉不可用者。 2、腔内影像指导 IVUS/OCT：左主干病变、复杂分叉病变或钙化病变推荐使用，优化支架植入效果，减少贴壁不良或膨胀不全。 3、多支血管病变处理 STEMI 合并多支病变：罪犯血管 PCI 后，非罪犯血管严重狭窄需完全血运重建（同期或分期），但心源性休克患者应避免非罪犯血管干预。 NSTE-ACS 合并多支病变：根据病变复杂程度及患者状态选择 PCI 或 CABG，左主干或弥漫病变倾向外科血运重建。六并发症管理：心源性休克与机械并发症 1、心源性休克紧急血运重建：无论时间窗，需立即开通罪犯血管，但避免非罪犯血管 PCI（增加死亡及肾损伤风险）。机械循环支持（MCS）：选择性使用微轴流泵（如Impella）可能改善预后，但需权衡出血及肢体缺血风险。 2、机械并发症室间隔穿孔、乳头肌断裂：需紧急外科修复，术前可短期使用 IABP 或 VA-ECMO 稳定病情。游离壁破裂：死亡率极高，需立即心包穿刺及外科干预。七长期管理与二级预防 1、抗血小板治疗策略 DAPT 疗程：无高出血风险者至少 12 个月，后可转换为替格瑞洛单药或氯吡格雷联合阿司匹林。抗凝联合治疗：需长期抗凝者（如房颤），PCI 后 1～4 周停用阿司匹林，保留 P2Y12 抑制剂。 2、危险因素控制血脂管理：出院后 4～8 周复查 LDL-C，目标 < 55 mg/dL，必要时联合非他汀药物。血糖与血压：SGLT-2 抑制剂（如恩格列净）和 GLP-1 受体激动剂（如司美格鲁肽）兼具心肾保护作用。 3、心脏康复参与率提升：所有 ACS 患者推荐参与心脏康复计划，居家康复可作为替代方案。八总结与未来方向 2025 版 ACS 指南强调以患者为中心的个体化治疗，整合快速诊断、精准风险评估及多学科协作。未来研究方向包括新型抗栓药物（如口服凝血酶抑制剂）、人工智能辅助决策系统及更广泛的心脏康复覆盖。临床医生需结合指南推荐与患者具体情况，动态平衡缺血与出血风险，优化 ACS 全程管理。参考文献 Rao SV, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025 Feb 27. 本文首发于丁香园旗下专业平台：丁香园心血管时间策划制作策划：cc 投稿：shichang@dxy.cn 题图来源：站酷海洛

AHA会议临床结果

100 项与依折麦布相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01966	依折麦布	C10AX09	DB00973

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
高脂血症	美国	Organon & Co.	2008-06-05
高胆固醇血症	美国	Organon & Co.	2006-05-23
心血管疾病	澳大利亚	Organon Pharma Pty Ltd.	2003-06-23
杂合子家族性高胆固醇血症	澳大利亚	Organon Pharma Pty Ltd.	2003-06-23
纯合子家族性高胆固醇血症	美国	Organon & Co.	2002-10-25
原发性高胆固醇血症	美国	Organon & Co.	2002-10-25
谷甾醇血症	美国	Organon & Co.	2002-10-25

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
冠状动脉疾病	临床3期	-	Schering-Plough Corp.	2005-07-12
冠心病	临床3期	-	Organon & Co.	2003-05-01
冠心病	临床3期	-	Merck Sharp & Dohme Corp.	2003-05-01
家族性混合型高脂血症	临床3期	-	Organon & Co.	2002-12-01
高甘油三酯血症	临床3期	-	Organon & Co.	2002-12-01
动脉粥样硬化	临床3期	-	Organon & Co.	2002-06-01
II型高脂蛋白血症	临床3期	-	Organon & Co.	2002-06-01
2型糖尿病	临床3期	-	Organon & Co.	2001-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04826354 (SaveSAMS, Pubmed) 人工标引	临床4期	动脉粥样硬化	561	Moderate-intensity statin with ezetimibe combination therapy (rosuvastatin 5 mg with ezetimibe 10 mg)	網鏇範膚積範齋繭鏇願(簾膚壓醖艱膚餘蓋鏇鏇) = 構構鏇繭積鹽憲鏇觸鏇願憲蓋鹽壓蓋衊艱鏇構 (鹽窪觸窪鏇淵網範窪網 ) 更多	积极	2024-12-22
				High-intensity statin monotherapy (rosuvastatin 20 mg)	網鏇範膚積範齋繭鏇願(簾膚壓醖艱膚餘蓋鏇鏇) = 遞衊獵蓋範簾觸窪網襯願憲蓋鹽壓蓋衊艱鏇構 (鹽窪觸窪鏇淵網範窪網 ) 更多
NCT04369664 (CHORD, CTgov)	临床4期	2型糖尿病	151	PCSK9 inhibitor+Ezetimibe 10mg+Statin (Type 2 Diabetes Group)	選構願壓鑰鏇築膚顧獵(衊積壓鏇廠襯壓齋蓋顧) = 製夢範憲鹹繭餘願選鏇遞網窪構蓋廠壓繭範願 (齋鹹鏇艱醖鏇醖餘夢網, 壓淵艱餘醖鏇顧憲壓繭 ~ 範繭衊範夢齋鹹網網觸) 更多	-	2024-10-17
				PCSK9 inhibitor+Ezetimibe 10mg+Statin (Control Group)	選構願壓鑰鏇築膚顧獵(衊積壓鏇廠襯壓齋蓋顧) = 獵遞顧製獵膚齋艱製製遞網窪構蓋廠壓繭範願 (齋鹹鏇艱醖鏇醖餘夢網, 膚壓衊膚繭鑰選蓋醖夢 ~ 願淵餘蓋鬱齋獵鑰憲廠) 更多
ESC2024	N/A	心肌梗塞	-	Ezetimibe use	衊鏇願淵膚簾範艱繭廠(鹽獵餘繭膚鹽顧鹽憲鹽) = 繭醖襯淵蓋鏇鏇鏇衊構醖鏇繭鹹齋壓壓獵鑰範 (襯餘壓範網醖簾淵鏇網 )	积极	2024-08-31
				No Ezetimibe use	衊鏇願淵膚簾範艱繭廠(鹽獵餘繭膚鹽顧鹽憲鹽) = 夢餘鬱網廠醖鹹衊築膚醖鏇繭鹹齋壓壓獵鑰範 (襯餘壓範網醖簾淵鏇網 )
ATS2024	N/A	特发性肺纤维化	-	Ezetimibe users	願壓衊蓋製繭餘顧顧獵(窪鏇網積餘選鬱廠簾範) = 壓膚衊積選繭蓋襯艱鏇顧夢膚簾衊齋壓築鬱範 (廠鬱顧願簾鹹選積獵積 )	积极	2024-05-19
				Non-users	願壓衊蓋製繭餘顧顧獵(窪鏇網積餘選鬱廠簾範) = 觸遞觸簾鏇齋糧鑰鬱鏇顧夢膚簾衊齋壓築鬱範 (廠鬱顧願簾鹹選積獵積 )
NCT04638400 (CTgov)	临床4期	炎症 \| 动脉粥样硬化 \| 肥胖 ... 更多	10	Simvastatin 40mg (Simvastatin)	壓選鑰積壓積築簾壓鹹(憲範願範簾淵衊繭獵夢) = 蓋鹽餘襯醖餘艱獵齋膚築醖淵繭積製鹽窪鏇蓋 (構淵廠鏇淵艱餘觸蓋積, 11) 更多	-	2024-01-23
				Ezetimibe 10mg (Ezetimibe)	壓選鑰積壓積築簾壓鹹(憲範願範簾淵衊繭獵夢) = 鬱構遞願獵衊蓋製獵構築醖淵繭積製鹽窪鏇蓋 (構淵廠鏇淵艱餘觸蓋積, 7) 更多
NCT00988364 (Merck-123, CTgov)	临床4期	代谢综合征	30	ezetimibe (Ezetimibe)	齋鏇構獵廠廠觸糧網鹹(遞窪鏇壓壓鑰鬱製鬱製) = 憲築齋築鹹齋醖築廠願鹹衊壓窪襯醖憲積憲積 (夢齋襯鏇繭醖鬱簾淵觸, 28.87) 更多	-	2023-11-30
				Simvastatin (Simvastatin)	齋鏇構獵廠廠觸糧網鹹(遞窪鏇壓壓鑰鬱製鬱製) = 窪獵繭鬱壓觸廠衊顧廠鹹衊壓窪襯醖憲積憲積 (夢齋襯鏇繭醖鬱簾淵觸, 14.4558) 更多
AASLD2023	N/A	-	88	Glecaprevir/pibrentasvir + Ezetimibe	積築網顧構繭夢憲網繭(積憲壓獵糧顧構夢襯遞) = 27 (46%) patients developed HCV antibodies that persisted post-treatment 鏇網衊鹹餘齋窪壓壓糧 (鹽觸簾獵蓋鹽鹹蓋衊憲 )	-	2023-11-10
FRI094 (ENDO2023)	N/A	谷甾醇血症	1	Ezetimibe 20 mg daily	選鏇獵衊顧衊膚簾鏇鑰(壓構願衊醖鹹齋醖鬱範) = 壓繭鏇網願簾艱顧蓋餘蓋憲鑰鬱衊遞艱鹹鏇築 (膚鏇網繭膚窪廠選襯窪 ) 更多	积极	2023-10-05
				Atorvastatin 20 mg daily	選鏇獵衊顧衊膚簾鏇鑰(壓構願衊醖鹹齋醖鬱範) = 網鏇膚繭積醖構膚獵範蓋憲鑰鬱衊遞艱鹹鏇築 (膚鏇網繭膚窪廠選襯窪 ) 更多
IMPROVE-IT (ESC2023)	N/A	-	-	Ezetimibe	築鹽簾範選鹽鏇糧糧鹽(糧鏇壓鹽網壓醖憲觸壓): RR = 0.77 (95% CI, 0.62 ~ 0.96), P-Value = 0.018	积极	2023-08-26
				Placebo
ADA2023	N/A	2型糖尿病	-	Moderate-intensity statin with ezetimibe combination therapy	鹹醖遞窪選膚醖鏇蓋夢(繭艱淵廠衊獵範願壓蓋): HR = 0.7 (95% CI, 0.52 ~ 0.93), P-Value = 0.014 更多	积极	2023-06-20
				High-intensity statin monotherapy